NCT04128995

Brief Summary

This study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P25-P50 for phase_4 diabetes-mellitus-type-2

Timeline
7mo left

Started Dec 2019

Longer than P75 for phase_4 diabetes-mellitus-type-2

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Dec 2019Dec 2026

First Submitted

Initial submission to the registry

October 11, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 16, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

December 15, 2019

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

March 24, 2026

Status Verified

March 1, 2026

Enrollment Period

7 years

First QC Date

October 11, 2019

Last Update Submit

March 21, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Glycemic Control

    Hemoglobin A1c of \<6.5%

    At one year

Secondary Outcomes (9)

  • Glycemic Control

    At two years

  • Glycemic Variability

    At one year

  • Beta Cell Function

    at 1 and 2 years

  • Alpha cell function

    at 1 and 2 years

  • Incretin Response

    at 1 and 2 years

  • +4 more secondary outcomes

Study Arms (3)

Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes

ACTIVE COMPARATOR

Youth with type 2 diabetes undergoing bariatric surgery, n=45

Procedure: Advanced Medical Therapy and Bariatric Surgery

Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes

ACTIVE COMPARATOR

Youth with type 2 diabetes receiving medical management, n=45

Drug: Advanced Medical Therapy

Bariatric Surgery in Youth with Obesity

ACTIVE COMPARATOR

Youth with no obesity undergoing bariatric surgery, n=10

Procedure: Bariatric Surgery

Interventions

Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes

Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes

Vertical Sleeve Gastrectomy for youth without type 2 diabetes

Also known as: Vertical Sleeve Gastrectomy
Bariatric Surgery in Youth with Obesity

Eligibility Criteria

Age13 Years - 19 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 13-19.9 years of age at time of signing the consent
  • Type 2 diabetes by the American Diabetes Association criteria
  • Negative diabetes-associated antibodies

You may not qualify if:

  • Any chronic oral steroids use within 60 days of enrollment
  • Current pancreatotoxic drugs
  • Chronic kidney or liver disease (except NAFLD or DKD)
  • Pregnancy, breast-feeding or intension of becoming pregnant
  • Prior bariatric surgery
  • History of malignancy
  • Current participation in another clinical trial that may affect study outcomes
  • Other conditions, that in the determination of the study investigator, may interfere with study participation
  • Age 13-19.9 years of age at time of signing the consent
  • Clinical indication to receive bariatric surgery
  • Known diabetes
  • Any chronic oral steroids use within 60 days of enrollment
  • Current pancreatotoxic drugs
  • Chronic kidney or liver disease (except NAFLD or DKD)
  • Pregnancy, breast-feeding or intension of becoming pregnant
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Children's Hospital Colorado

Aurora, Colorado, 80045, United States

Location

Lurie Children's Hospital

Chicago, Illinois, 60611, United States

Location

Cincinnati Childrens

Cincinnati, Ohio, 45229, United States

Location

Related Publications (1)

  • Shah AS, Helmrath MA, Inge TH, Xanthakos SA, Kelsey MM, Jenkins T, Trout AT, Browne L, Nadeau KJ. Study protocol: a prospective controlled clinical trial to assess surgical or medical treatment for paediatric type 2 diabetes (ST2OMP). BMJ Open. 2021 Aug 13;11(8):e047766. doi: 10.1136/bmjopen-2020-047766.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Pediatric Obesity

Interventions

Bariatric Surgery

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesObesityOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

BariatricsObesity ManagementTherapeuticsSurgical Procedures, Operative

Study Officials

  • Amy S Shah, MD MS

    Cincinnati Childrens Hospital Medical Center

    PRINCIPAL INVESTIGATOR
  • Kristen J Nadeau, MD MS

    Children's Hospital Colorado

    PRINCIPAL INVESTIGATOR
  • Michael A Helmrath, MD MS

    Children's Hospital Medical Center, Cincinnati

    PRINCIPAL INVESTIGATOR
  • Thomas H Inge, MD PhD

    Ann & Robert H Lurie Children's Hospital of Chicago

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Open label prospective clinical trial. Primary comparison is medical (n=45) vs surgical (n=45) groups. Patients with obesity and no diabetes (n=10) are a comparator group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Department of Pediatrics

Study Record Dates

First Submitted

October 11, 2019

First Posted

October 16, 2019

Study Start

December 15, 2019

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

March 24, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

The PI's will also report a of summary results information (including adverse events) after completion of the study. All data from the study including any negative findings will be published in peer reviewed manuscripts.

Locations